|
Synonyms: ACD79B-VCMMAE | polatuzumab vedotin-piiq | Polivy® | RG-7596 | RG7596 | RO5541077-000
polatuzumab vedotin is an approved drug (FDA (2019), EMA (2020))
Compound class:
Antibody
Comment: Polatuzumab vedotin is an antibody drug conjugate containing an anti-CD79b monoclonal antibody linked to the toxin monomethyl auristatin E (MMAE, aka vedotin; PubChem CID 11542188).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. Peptide sequence matches identify US8088378 as the claiming patent [1]. |
| No information available. |
Summary of Clinical Use  |
| The EMA granted polatuzumab vedotin orphan designation for the treatment of aggressive lymphoma (relapsed/refractory diffuse large B-cell lymphoma; DLBCL) in April 2018. In June 2019, the FDA granted accelerated approval for the use of polatuzumab vedotin (Polivy®) [2] as a treatment for DLBCL that has progressed following treatment with at least two previous therapies. Polivy is to be used in combination with bendamustine and a rituximab product in these patients. This accelerated approval was granted based on results from NCT02257567 [2]. Click here to link to ClinicalTrials.gov's full list of polatuzumab vedotin trials. Full EMA marketing authorisation was granted in January 2020. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02257567 | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | Phase 1/Phase 2 Interventional | Hoffmann-La Roche | ||
